NewsHK
The Schall Law Firm, a Los Angeles-based national shareholder rights litigation firm, has reminded investors in GeneDx Holdings Corp.
(NASDAQ: WGS) of an active class action lawsuit alleging violations of federal securities law.
The suit targets the genomic diagnostics company under Sections 10(b) and 20(a) of the Securities Exchange Act, the two provisions most commonly invoked in shareholder fraud claims — one covering market manipulation and misrepresentation, the other extending liability to controlling persons.
What the Lawsuit Alleges The complaint rests on the twin pillars of Exchange Act securities litigation: Section 10(b), which prohibits fraudulent schemes and material misstatements in connection with the purchase or sale of securities, and Section 20(a), which holds those who control a violating entity jointly and severally liable.
Keep reading